OncoMatch/Clinical Trials/NCT05440227
PG2 Injection for the Treatment of moderate-to Severe Fatigue in Breast Cancer Patients
Is NCT05440227 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies PG2 Lyo. for cancer-related fatigue.
Treatment: PG2 Lyo. — The objective of this study is to assess the efficacy of weekly PG2 regimen as a complementary treatment for patients with recurrent unresectable (local or regional) or metastatic breast cancer who experienced moderate to severe fatigue while receiving chemotherapies.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Disease stage
Required: Stage III, IV
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Lab requirements
Blood counts
hgb ≥ 10 g/dl (patients must not be transfused ≤ 14 days to meet this criterion)
Kidney function
creatinine ≤ 1.2 x uln
Liver function
ast (sgot) or alt (sgpt) ≤1.5 x uln (or ≤5.0 x uln for patients with liver metastases)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05440227 currently recruiting?
Yes, this trial is currently recruiting patients.
What disease stage is eligible?
Stage III or IV is required.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify